NCT03378596

Brief Summary

Post-exercise hypotension (PEH) is a established phenomenon as one of the non-pharmacological ways of reducing blood pressure, producing important impacts, particularly in hypertensive individuals. However, the factors involved in the magnitude and duration of this effect are relatively little studied. Thus, the bioavailability of vasodilatation mediators may maximize the duration and magnitude of PEH. In this sense, the objective of the present project will be to verify the impact of L-citrulline associated with L-arginine supplementation on the acute blood pressure response after an aerobic exercise session. Approximately 80 adults (40 normotensive and 40 hypertensive) will be selected. The sample will be submitted to measurements of body mass, height and resting blood pressure. After the minimum interval of 48 h, subjects will be randomly submitted to four experimental situations (exercise/L-citrulline, exercise/L-arginine, exercise/placebo, exercise/L-citrulline + L-arginine). The exercise sessions (40 min in treadmill at 60% of FCres) will be performed with a minimum interval of 48 h. After each session, the blood pressure of the sample will be recorded during 24 hours. For data analysis, blood pressure values will be plotted in average of the wakefulness and average of the sleep periods and average of the 24 hours. The comparisons will be made through the ANOVA (repeated measures), following the recommended assumptions. It is hoped that the results of this project will collaborate to the knowledge regarding non-pharmacological models aimed at the prevention and treatment of hypertension in normotensive and hypertensive patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable hypertension

Timeline
Completed

Started Jan 2018

Shorter than P25 for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 14, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 20, 2017

Completed
13 days until next milestone

Study Start

First participant enrolled

January 2, 2018

Completed
29 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2018

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2018

Completed
Last Updated

December 27, 2017

Status Verified

December 1, 2017

Enrollment Period

29 days

First QC Date

December 14, 2017

Last Update Submit

December 22, 2017

Conditions

Keywords

Post-Exercise HypotensionExerciseArginineCitrulline

Outcome Measures

Primary Outcomes (1)

  • Ambulatorial Blood Pressure Monitoring

    The ambulatorial blood pressure measurements will be taken with oscillometric device (Dyna-MAPA - São Paulo, Brazil) attached on the left arm. The participants will received instructions to keep the arm stand during the measures. The monitor will be setting to register the systolic and diastolic blood pressure and heart rate every 20 minutes during "daytime" (08:00am to 11:00pm) and every 30 minutes during "night-time" (11:00pm to 08:00am) to reduce sleep disturbs. The device screen will be electronically blinded to avoid feedback. The metric measures will be reported by millimeters of mercury (mmHg).

    24 hours

Study Arms (4)

L-citrulline & L-arginine

EXPERIMENTAL

L-citrulline (6 grams) L-arginine (8 grams)

Dietary Supplement: L-citrulline + L-arginine

L-citrulline & Placebo

ACTIVE COMPARATOR

L-citrulline (6 grams) Placebo (6 grams)

Dietary Supplement: L-citrullineDietary Supplement: Placebo

L-arginine & Placebo

ACTIVE COMPARATOR

L-arginine (8 grams) Placebo (6 grams)

Dietary Supplement: L-arginineDietary Supplement: Placebo

Placebo

ACTIVE COMPARATOR

Placebo (6 grams)

Dietary Supplement: Placebo

Interventions

L-citrulline + L-arginineDIETARY_SUPPLEMENT

L-citrulline + L-arginine - sachet dissolved in water

L-citrulline & L-arginine
L-arginineDIETARY_SUPPLEMENT

L-arginine - sachet dissolved in water

L-arginine & Placebo
L-citrullineDIETARY_SUPPLEMENT

L-citrulline - sachet dissolved in water

L-citrulline & Placebo
PlaceboDIETARY_SUPPLEMENT

Placebo (corn starch) - sachet dissolved in water

L-arginine & PlaceboL-citrulline & PlaceboPlacebo

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Hypertensive and Normotensive, without osteoarticular disabilities and medical authorization to physical exercise practice.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Juliano Casonatto

Londrina, Paraná, 86025-170, Brazil

RECRUITING

Related Publications (8)

  • Borg G. Borg's Perceived Exertion and Pain Scales. Champaign: Human Kinetics; 1998.

    BACKGROUND
  • Gordon CC, Chumlea WC, Roche AF. Stature, recumbent length, and weight. Lohman TG, Roche AF, Martorell R, editors. Champaign: Human Kinetics Books; 1988. 3-8 p.

    BACKGROUND
  • Coleman A, Freeman P, Steel S, Shennan A. Validation of the Omron MX3 Plus oscillometric blood pressure monitoring device according to the European Society of Hypertension international protocol. Blood Press Monit. 2005 Jun;10(3):165-8. doi: 10.1097/00126097-200506000-00009.

    PMID: 15923819BACKGROUND
  • Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ; Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005 Jan;45(1):142-61. doi: 10.1161/01.HYP.0000150859.47929.8e. Epub 2004 Dec 20.

    PMID: 15611362BACKGROUND
  • Quintana DS, Heathers JA, Kemp AH. On the validity of using the Polar RS800 heart rate monitor for heart rate variability research. Eur J Appl Physiol. 2012 Dec;112(12):4179-80. doi: 10.1007/s00421-012-2453-2. Epub 2012 Jul 13. No abstract available.

    PMID: 22790488BACKGROUND
  • Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996 Mar 1;93(5):1043-65. No abstract available.

    PMID: 8598068BACKGROUND
  • Casonatto J, Tinucci T, Dourado AC, Polito M. Cardiovascular and autonomic responses after exercise sessions with different intensities and durations. Clinics (Sao Paulo). 2011;66(3):453-8. doi: 10.1590/s1807-59322011000300016.

    PMID: 21552672BACKGROUND
  • Domingues V, Cavalari JV, Grandolfi K, Aguiar AF, Borghi SM, Casonatto J. Acute Effects of Citrulline Malate Supplementation on Nocturnal Blood Pressure Dipping After Exercise in Hypertensive Patients: A Randomized, Placebo-Controlled Trial. J Diet Suppl. 2024;21(6):868-880. doi: 10.1080/19390211.2024.2414052. Epub 2024 Oct 10.

MeSH Terms

Conditions

HypertensionPost-Exercise HypotensionMotor Activity

Interventions

CitrullineArginine

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesOrthostatic IntolerancePrimary DysautonomiasAutonomic Nervous System DiseasesNervous System DiseasesHypotensionBehavior

Intervention Hierarchy (Ancestors)

Amino Acids, DiaminoAmino AcidsAmino Acids, Peptides, and ProteinsAmino Acids, BasicAmino Acids, Essential

Central Study Contacts

Juliano Casonatto, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor, Clinical Research

Study Record Dates

First Submitted

December 14, 2017

First Posted

December 20, 2017

Study Start

January 2, 2018

Primary Completion

January 31, 2018

Study Completion

February 28, 2018

Last Updated

December 27, 2017

Record last verified: 2017-12

Locations